(Q30843316)

27 June 2017

1 reference

Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data (English)

1 reference

27 June 2017

1 reference

1 reference

1 reference

Bruce Neal

15

0 references

Donald Lloyd-Jones

object named as

Donald Lloyd-Jones

7

0 references

Johan Sundström

2

object named as

Johan Sundström

1 reference

27 June 2017

5

Rod Jackson

1 reference

27 June 2017

12

Anushka Patel

1 reference

27 June 2017

Blood Pressure Lowering Treatment Trialists' Collaboration

1

1 reference

27 June 2017

Hisatomi Arima

3

1 reference

27 June 2017

Mark Woodward

4

1 reference

27 June 2017

Kunal Karmali

6

1 reference

27 June 2017

Colin Baigent

8

1 reference

27 June 2017

Jonathan Emberson

9

1 reference

27 June 2017

Kazem Rahimi

10

1 reference

27 June 2017

Stephen MacMahon

11

1 reference

27 June 2017

Vlado Perkovic

13

1 reference

27 June 2017

Fiona Turnbull

14

1 reference

27 June 2017

language of work or name

English

0 references

publication date

1 August 2014

1 reference

27 June 2017

1 reference

27 June 2017

384

1 reference

27 June 2017

591-598

1 reference

27 June 2017

9943

1 reference

Management of raised blood pressure in New Zealand: a discussion document

27 June 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961212-5

7 January 2021

2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961212-5

7 January 2021

Risk assessment and lipid modification for primary and secondary prevention of cardiovascular disease: summary of NICE guidance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961212-5

7 January 2021

European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961212-5

7 January 2021

Management of hypertension: summary of NICE guidance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961212-5

7 January 2021

2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961212-5

7 January 2021

The 2013 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961212-5

7 January 2021

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961212-5

7 January 2021

Blood pressure-dependent and independent effects of agents that inhibit the renin–angiotensin system

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961212-5

7 January 2021

Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961212-5

7 January 2021

Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961212-5

7 January 2021

Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961212-5

7 January 2021

Preventing microalbuminuria in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961212-5

7 January 2021

Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961212-5

7 January 2021

Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961212-5

7 January 2021

Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961212-5

7 January 2021

Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961212-5

7 January 2021

Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961212-5

7 January 2021

Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: The Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961212-5

7 January 2021

Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961212-5

7 January 2021

Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961212-5

7 January 2021

Treatment of hypertension in patients 80 years of age or older

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961212-5

7 January 2021

The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961212-5

7 January 2021

Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961212-5

7 January 2021

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961212-5

7 January 2021

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961212-5

7 January 2021

The Effects of Blood Pressure Reduction in Older Patients: An Overview of Five Randomized Controlled Trials in Elderly Hypertensives

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961212-5

7 January 2021

Tight versus standard blood pressure control in patients with hypertension with and without cardiovascular disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961212-5

7 January 2021

Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961212-5

7 January 2021

Updated New Zealand cardiovascular disease risk-benefit prediction guide

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961212-5

7 January 2021

European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961212-5

7 January 2021

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961212-5

7 January 2021

Prediction of benefit from carotid endarterectomy in individual patients: a risk-modelling study. European Carotid Surgery Trialists' Collaborative Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961212-5

7 January 2021

An independently derived and validated predictive model for selecting patients with myocardial infarction who are likely to benefit from tissue plasminogen activator compared with streptokinase

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961212-5

7 January 2021

Selection of thrombolytic therapy for individual patients: development of a clinical model. GUSTO-I Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961212-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961212-5

1 reference

7 January 2021

Individualized guidelines: the potential for increasing quality and reducing costs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961212-5

7 January 2021

Improving the cost-effectiveness of cardiovascular disease prevention in Australia: a modelling study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961212-5

7 January 2021

Cost-effectiveness analysis of hypertension guidelines in South Africa: absolute risk versus blood pressure level

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961212-5

7 January 2021

The influence of absolute cardiovascular risk, patient utilities, and costs on the decision to treat hypertension: a Markov decision analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961212-5

7 January 2021

Estimating treatment effects for individual patients based on the results of randomised clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961212-5

7 January 2021

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961212-5

7 January 2021

10.1016/S0140-6736(14)61212-5

Identifiers

DOI

1 reference

27 June 2017

1 reference